Why incorporate a senolytic protocol into your health routine?

Over time, certain cells in our body enter a state of senescence. Those cells, sometimes called zombie cells, stop dividing, resist to elimination and can produce inflammatory molecules that are harmful to surrounding tissues. Their accumulation is being studied for its role in aging signs. They are considered a key driver of what is referred to as ‘inflammaging’; the inflammation associated with aging processes which accelerate and increase the risk of illness.

 

The BASE Protection protocol fits into an innovative strategy designed to mitigate the effects of cellular aging. It combines standardized antioxidants derived from plants (BASE Protection; Fisetin, quercetin, and EGCG combined with omega-3 fatty acids in monoglyceride form (BASE MAG-O3™ Daily): a patented technology for an optimized absorption.

 

Phase 1 – Elimination (14 days, every 2 months)

**Note: Discontinuation of omega-3 supplementation is recommended during the elimination phase to ensure optimal efficacy of the protocol.

Product used: BASE Protection (NPN 80131183)

Formulated with a standardized synergistic combination of:

  • Fisetin (100mg)
  • Quercetin (500mg)
  • Green Tea Extract (EGCG) (50mg)

Authorized claims:

  • Provides antioxidants
  • Helps protect cells from oxidative damage caused by free radicals
  • Used in herbal medicine as a vascular protectant.

 

Scientific studies conducted by our research team indicate that BASE Protection could potentially:

  • Reduce the proportion of senescent cells in culture from the first week (-29% to – 34%)
  • Act through a targeted effect to support cellular renewal
  • Modulate responses associated with oxidative stress, which may indirectly support immune balance

These observations are based on internal preclinical models and should not be interpreted as therapeutic claims.

 

Phase 2 – Cellular maintenance (2 months)

Product used:

  • BASE MAG-O3™ Quotidien (NPN 80123170)
  • or BASE MAG-O3™ MAG-EPA (NPN 80122883)

 

Authorized claims :

  • Source of omega-3 fatty acids (EPA and DHA), contributing to the maintenance of good health.
  • Contributes to the maintenance of cardiovascular and cognitive health.
  • Helps maintain normal blood triglyceride levels.
  • Contributes to maintaining healthy cell membranes.

 

Internal data

  • Rapid improvement of the omega-3 index.
  • Optimization of the AA:EPA ratio, a biomarker associated with inflammatory balance.
  • Superior absorption of other nutrients like K2 and CoQ10 vitamins.

 

A simple and efficient protocol to repeat 5 times a year

Period Product Recommended dosage
Day 1 to 14 BASE Protection 2 capsules daily with a food
Day 15 to 60 BASE MAG-O3™ 1 to 6 capsules daily, depending on the product

** It is recommended to consult a healthcare professional if BASE Protection is to be used beyond two months.

 

Documented support (based on our internal studies).

Our research suggests that this combined protocol:

  • May potentially reduce by up to 50% biomarkers associated with cellular senescence in humans.
  • Is potentially associated with a significant improvement in estimated biological age in a pilot cohort (average reduction of 12 years over 7 months).
  • Rapidly increases the omega-3 index into the optimal range of 8% or higher.
  • May help regulate oxidative stress and potentially support cellular energy maintenance and healthy longevity.

 

Conclusion

BASE Protection is part of an integrated strategy to support healthy aging. By combining powerful antioxidant ingredients with next-generation omega-3s, this protocol promotes a proactive approach to cellular longevity and metabolic well-being.

 

References:

Vicencio, J. M., Galluzzi, L., Tajeddine, N., Ortiz, C., Criollo, A., Tasdemir, E., … & Kroemer, G. (2008).Senescence, apoptosis or autophagy? When a damaged cell must decide its path–a mini-review. Gerontology,54(2), 92-99.

Childs, B. G., Baker, D. J., Kirkland, J. L., Campisi, J., & Van Deursen, J. M. (2014). Senescence andapoptosis: dueling or complementary cell fates?. EMBO reports, 15(11), 1139-1153.

Hu, L., Li, H., Zi, M., Li, W., Liu, J., Yang, Y., … & He, Y. (2022). Why senescent cells are resistant toapoptosis: an insight for senolytic development. Frontiers in Cell and Developmental Biology, 10, 822816.

Grynkiewicz G, Demchuk OM. New Perspectives for Fisetin. Front Chem. 2019;7:697. Published 2019 Oct30. doi:10.3389/fchem.2019.00697

Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan.EBioMedicine. 2018;36:18-28. doi:10.1016/j.ebiom.2018.09.015

Zoico E, Nori N, Darra E, et al. Senolytic effects of quercetin in an in vitro model of pre-adipocytes andadipocytes induced senescence. Sci Rep. 2021;11(1):23237. Published 2021 Dec 1. doi:10.1038/s41598-021-02544-0

Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolyticdrugs. Aging Cell. 2015;14(4):644-658. doi:10.1111/acel.12344

 

Patent

WO2023122827 – POLYUNSATURATED FATTY ACID MONOGLYCERIDES, COMPOSITIONS,METHODS AND USES THEREOF – 3 avril 2025.